Evidence map›Paper›PMID 40486267›Full record

ArticleGastro hep advances2025

The Involvement of Oral Pathogenic Bacteria,

Taku Kitano, Shintaro Okumura, Tomonori Matsumoto, Shigeru Tsunoda, Tatsuto Nishigori, Kazutaka Obama, Eiji Hara

Abstract read
In one paragraph

Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. IntratumoralAnnals of gastroenterological surgery · 2026
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Taku KitanoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shintaro OkumuraDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tomonori MatsumotoDepartment of Molecular Biology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
Shigeru TsunodaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tatsuto NishigoriDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kazutaka ObamaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Eiji HaraDepartment of Molecular Biology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: While esophageal microbiota is known to be altered in patients with esophageal adenocarcinoma (EAC), specific bacterial species contributing to the pathogenesis remain unclear. We aimed to identify bacteria associated with the pathogenesis of EAC and to investigate their potential role. Methods: Microbiota in EAC tissues was explored by 16S-rRNA sequencing. The impact of intratumoral bacteria on tumor microenvironment was histologically evaluated. The influence by pathological bacteria on cancer cells was examined by the treatment of OE33 cell line with cultural supernatant of bacteria. Results: Oral pathogenic bacteria previously reported to increase in colorectal cancer patients were detected in 7 out of 31 EAC patients and were associated with poor prognosis. Intratumoral bacterial infiltration was significantly accompanied with local neutrophil infiltration and nuclear positivity of NF-κB in cancer cells. Furthermore, the culture supernatant of Conclusion: Intratumoral microbiota, especially the infiltration of oral pathogenic bacteria such as

Indexed as

DNA DamageEsophageal Adenocarcinoma (EAC)Fusobacterium nucleatum Subspecies animalisOral Pathogenic BacteriaReactive Oxygen Species (ROS)

Identifiers

PMID40486267
PMCPMC12144443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.